ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions
View by Date

Tuesday, November 15, 2016

9:00AM-11:00AM
Abstract Number: 2969
10 Year Retrospective Analysis of 276 Cases of Histopathologically Confirmed Leukocytoclastic Vasculitis
Vasculitis - Poster III: Rarer Vasculitides
9:00AM-11:00AM
Abstract Number: 2285
12/15-Lipoxygenase Inhibition By ML351 Protects Against Uric Acid Crystal-Induced Acute Arthritis in Mice
Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease
9:00AM-11:00AM
Abstract Number: 2973
A Comparison of Caregiving Burden and Impact in Systemic Vasculitis Versus Other Conditions
Vasculitis - Poster III: Rarer Vasculitides
9:00AM-11:00AM
Abstract Number: 2911
A Comparison of Gastrointestinal Disease Severity in African American and Caucasian Scleroderma Patients
Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III
9:00AM-11:00AM
Abstract Number: 2601
A Cytometric Assay for Monitoring Adalimumab Immunogenicity and Drug Concentrations Can Distinguish Anti-Adalimumab Antibodies from Interference
Rheumatoid Arthritis – Small Molecules, Biologics and Gene Therapy - Poster III
9:00AM-11:00AM
Abstract Number: 2240
A Descriptive Analysis of Real-World Treatment Patterns in a Turkish Rheumatology Population That Continued Innovator Infliximab (Remicade) Therapy or Switched to Biosimilar Infliximab
Health Services Research - Poster III
9:00AM-11:00AM
Abstract Number: 2266
A Melanocortin Fusion Peptide (AQB-565) Optimized for Melanocortin Receptor Engagement Significantly Reduces Inflammation in an In Vivo model of Acute Gout
Innate Immunity and Rheumatic Disease - Poster II
9:00AM-11:00AM
Abstract Number: 2780
A Modification of the Psoriatic Arthritis Disease Activity Score (mPASDAS) Using SF-12 As a Measure of Quality of Life
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III
9:00AM-11:00AM
Abstract Number: 2295
A Non-Linear Relationship Between Physical Activity and Serum Uric Acid Concentrations: Nhanes 2003-2004
Metabolic and Crystal Arthropathies - Poster II: Epidemiology and Mechanisms of Disease
9:00AM-11:00AM
Abstract Number: 2561
A Novel Pharmacological Action of MTX on RA Fibroblast-like Synoviocytes Via Circadian Clock Genes
Rheumatoid Arthritis – Human Etiology and Pathogenesis - Poster III
9:00AM-11:00AM
Abstract Number: 2343
A Phase 2, Multi-Center, Randomized, Double-Blind, Active-Controlled, Parallel Group Study to Evaluate the Safety and Dose Effectiveness of Intradermal Injections of Purified Apis Mellifera Toxin to Improve Pain and Physical Function in Patients with Osteoarthritis of the Knee
Osteoarthritis – Clinical Aspects - Poster II
9:00AM-11:00AM
Abstract Number: 2724
A Prospective Study of Ankylosing Spondylitis in China with Smart Management System for Spondyloarthritis: Study Design and Baseline Characteristics of the 449 Recruited Patients
Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment - Poster III
9:00AM-11:00AM
Abstract Number: 2488
A Randomised Controlled Trial Evaluating the Effect of Adalimumab upon Biomarkers of Cardiovascular Risk in ACPA-Positive Rheumatoid Arthritis
Rheumatoid Arthritis – Clinical Aspects - Poster III: Treatment – Monitoring, Outcomes, Adverse Events
9:00AM-11:00AM
Abstract Number: 8L
A Randomized, Double-Blind, Placebo-Controlled Study of Bimagrumab in Patients with Sporadic Inclusion Body Myositis
ACR Late-Breaking Poster Session
9:00AM-11:00AM
Abstract Number: 2250
A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Health Services Research - Poster III
  • 1
  • 2
  • 3
  • …
  • 69
  • Next Page»
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology